ArticlePloS one2026
Plasma gelsolin as a potential biomarker for intrauterine inflammation in pregnant women with preterm premature rupture of membranes: A pilot study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGelsolin is an actin-binding protein, the blood levels of which decrease in response to inflammation and tissue injury. However, the dynamics of gelsolin during pregnancy and its relationship with intrauterine inflammation remain unclear. In cases of preterm premature rupture of membranes, conventional indicators such as white blood cell (WBC) count and C-reactive protein (CRP) have known limitations, and reliable biomarkers for predicting intrauterine inflammation are limited. In this study, we investigated changes in plasma gelsolin concentrations during pregnancy and evaluated their association with intrauterine inflammation in patients with preterm premature rupture of membranes.
methodsIn this pilot study, plasma gelsolin concentrations were measured by enzyme-linked immunosorbent assay in healthy pregnant women and in patients with preterm premature rupture of membranes. In healthy pregnancies, samples from the first, second, and third trimesters were analyzed. In cases with preterm premature rupture of membranes, serial measurements were performed from the time of membrane rupture to delivery. Correlation analyses with inflammatory markers (C-reactive protein and white blood cell) were conducted. Additionally, immunohistochemical staining for gelsolin was performed on placental tissues from chorioamnionitis cases and controls to compare expression levels and distribution patterns.
resultsIn healthy pregnant women, plasma gelsolin levels significantly decreased as pregnancy progressed. In cases with preterm premature rupture of membranes, plasma gelsolin levels showed a significant negative correlation with C-reactive protein and tended to decrease over time following membrane rupture. Immunohistochemical staining revealed a trend toward an increased number of gelsolin-positive cells in the chorionic membrane of chorioamnionitis cases.
conclusionPlasma gelsolin decreases with the progression of pregnancy and intrauterine inflammation and may particularly reflect the progression of intrauterine inflammation in cases of preterm premature rupture of membrane. Gelsolin has the potential to serve as a novel biomarker for detecting inflammatory conditions that are not readily identified by conventional markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.